Open-label dose-escalation on study of oral 1-octanol in patients with essential tremor

H. A. Shill, K. O. Bushara, Z. Mari, M. Reich, M. Hallett

Research output: Contribution to journalArticle

Abstract

Twenty-one single oral doses of 1-octanol were given to patients with essential tremor (ET) in an open-label dose-escalation study. The drug was well tolerated up to 64 mg/kg. The main side effect was an unusual taste. No overt intoxication was seen. There was evidence for efficacy, with a significant reduction in tremor amplitude as measured by accelerometry and handwriting that was maximal at 2 hours. Higher doses may produce more sustained benefit.

Original languageEnglish (US)
Pages (from-to)2320-2322
Number of pages3
JournalNeurology
Volume62
Issue number12
StatePublished - Jun 22 2004
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Open-label dose-escalation on study of oral 1-octanol in patients with essential tremor'. Together they form a unique fingerprint.

  • Cite this

    Shill, H. A., Bushara, K. O., Mari, Z., Reich, M., & Hallett, M. (2004). Open-label dose-escalation on study of oral 1-octanol in patients with essential tremor. Neurology, 62(12), 2320-2322.